{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:05:50Z","timestamp":1757624750438,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jlb.2023.100128","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:30:35Z","timestamp":1700238635000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Liquid biopsy for lung cancer: A cross section on the diagnostic routine experience of a referral Italian institution"],"prefix":"10.1016","volume":"2","author":[{"given":"Caterina","family":"de Luca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariantonia","family":"Nacchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ingenito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriana","family":"Conticelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Gridelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Parente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2023.100128_bib1","first-page":"10","article-title":"Cancer statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.jlb.2023.100128_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jlb.2023.100128_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2023.100128_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"AURA3 investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jlb.2023.100128_bib5","doi-asserted-by":"crossref","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018, 1;378:113-125.","DOI":"10.1056\/NEJMoa1713137"},{"key":"10.1016\/j.jlb.2023.100128_bib6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jlb.2023.100128_bib7","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jlb.2023.100128_bib8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2023.100128_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2023.100128_bib10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2023.100128_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jlb.2023.100128_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2023.100128_bib13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jlb.2023.100128_bib14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/2159-8290.CD-NB2019-073","article-title":"AMG 510 first to inhibit \"Undruggable\" KRAS","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2023.100128_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2023.100128_bib16","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.21037\/jtd.2020.01.19","article-title":"KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting","volume":"12","author":"Nacchio","year":"2020","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jlb.2023.100128_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-022-01505-z","article-title":"Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jlb.2023.100128_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jclinpath-2018-205386","article-title":"Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples","volume":"72","author":"Pepe","year":"2019","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jlb.2023.100128_bib19","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2023.100128_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41571-020-0423-x","article-title":"Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice","volume":"18","author":"Aggarwal","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jlb.2023.100128_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2020.08.008","article-title":"Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients - a single centre experience","volume":"149","author":"Dall'Olio","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jlb.2023.100128_bib22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2017.8","article-title":"Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients","volume":"116","author":"Malapelle","year":"2017","journal-title":"Br J Cancer"},{"issue":"Suppl 13","key":"10.1016\/j.jlb.2023.100128_bib23","doi-asserted-by":"crossref","first-page":"S1383","DOI":"10.21037\/jtd.2017.06.97","article-title":"Cell free DNA analysis by SiRe\u00ae next generation sequencing panel in non small cell lung cancer patients: focus on basal setting","volume":"9","author":"Pisapia","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"issue":"6","key":"10.1016\/j.jlb.2023.100128_bib24","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s13277-012-0465-5","article-title":"EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study","volume":"33","author":"de Mello","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jlb.2023.100128_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide frequency of commonly detected EGFR mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch Pathol Lab Med"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195423001285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195423001285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T16:21:16Z","timestamp":1757434876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195423001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"alternative-id":["S2950195423001285"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2023.100128","relation":{},"ISSN":["2950-1954"],"issn-type":[{"type":"print","value":"2950-1954"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy for lung cancer: A cross section on the diagnostic routine experience of a referral Italian institution","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2023.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}